Skip to content
value.today

Adial Pharmaceuticals, L.L.C.

🇺🇸 Charlottesville, Virginia, USAPharmaceuticalsFounded 2010
Total raised
$7 M
2 rounds on record
Latest round
$3 M
Jun 2013
First round on record
Mar 2011
Today
Went public
See the company page

Adial Pharmaceuticals, L.L.C. is listed today as Adial Pharmaceuticals, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding, 5 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Adial Pharmaceuticals, L.L.C.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2025$4 MPrivate placement after listing$2 to $10 million

Adial Pharmaceuticals, L.L.C.: Private sale, Nov 2025

Investors in this round

1 investor had bought by the notice of Dec 3, 2025: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$228,549
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cary J. Claiborne · Executive Officer, Director · Chief Executive Officer
  • Tony W. Goodman · Executive Officer, Director · Chief Operating Officer
  • Vinay J. Shah · Executive Officer · Chief Financial Officer
  • James K. Anderson · Director
  • James W. Newman, Jr. · Director
  • Kevin W. Schuyler, CFA · Director
  • Robertson H. Gilliland · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • A.G.P./Alliance Global Partners (CRD 000005361) · New York, New YorkSold in NY

Remarks in the notice

  • On the amounts: “Consists of $0.31 per share that may be received upon future exercise of warrants to purchase up to 13,823,512 shares of common stock.”

Signed by Cary J. Claiborne, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 3, 2025. Read the notice at the SEC.

optionsSEC
May 2025$5 MPrivate placement after listing$2 to $10 million

Adial Pharmaceuticals, L.L.C.: Private sale, May 2025

Investors in this round

1 investor had bought by the notice of May 14, 2025.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cary J. Claiborne · Executive Officer, Director · Chief Executive Officer
  • Tony W. Goodman · Executive Officer, Director · Chief Operating Officer
  • Vinay J. Shah · Executive Officer · Chief Financial Officer
  • James K. Anderson · Director
  • James W. Newman, Jr. · Director
  • Kevin W. Schuyler, CFA · Director
  • Robertson H. Gilliland · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • A.G.P./Alliance Global Partners (CRD 000005361) · New York, New YorkSold in NY

Remarks in the notice

  • On the amounts: “Consists of $0.74 per share that may be received upon future exercise of warrants to purchase up to 6,507,270 shares of common stock.”

Signed by Cary J. Claiborne, Chief Executive Officer. Source: SEC Form D, newest notice filed May 14, 2025. Read the notice at the SEC.

optionsSEC
Oct 2023$4 MPrivate placement after listing$2 to $10 million

Adial Pharmaceuticals, L.L.C.: Private sale, Oct 2023

Investors in this round

1 investor had bought by the notice of Oct 26, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$320,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bankole A. Johnson · Executive Officer
  • Cary J. Claiborne · Executive Officer, Director
  • Joseph M. Truluck · Executive Officer
  • James K. Anderson · Director
  • James W. Newman, Jr. · Director
  • Kevin W. Schuyler, CFA · Director
  • Robertson H. Gilliland · Director
  • Tony W. Goodman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “Includes placement agent fee of 7% & management fee of 1% of the aggregate gross proceeds of the offering. The issuer issued to placement agent designees warrants to purchase up to 85,106 shares at an exercise price of $3.25 and paid offering expenses”
  • On the use of proceeds: “While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.”
  • On a merger: “The Company issued pre-funded warrants, series A warrants and series B warrants , each warrant to purchase one share of common stock”

Signed by Cary J. Claiborne, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 26, 2023. Read the notice at the SEC.

equity, optionsSEC
Feb 2022$10 MPrivate placement after listing$10 to $50 million

Adial Pharmaceuticals, L.L.C.: Private sale, Feb 2022

Investors in this round

1 investor had bought by the notice of Feb 17, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$700,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bankole A. Johnson · Executive Officer
  • Cary W. Claiborne · Executive Officer, Director
  • Joseph M. Truluck · Executive Officer
  • William B. Stilley, III · Executive Officer, Director
  • James K. Anderson · Director
  • James W. Newman, Jr. · Director
  • Kevin W. Schuyler, CFA · Director
  • Robertson H. Gilliland · Director
  • Tony W. Goodman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in CA, IL, NY

Remarks in the notice

  • On fees: “Commission was paid for the securities issued in the registered direct offering”
  • On the amounts: “The Issuer issued securities in a registered direct offering for gross proceeds of approximately $10,000,000 and warrants in a concurrent private placement having an aggregate exercise price of approximately $10,000,000”
  • On the use of proceeds: “While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.”

Signed by William B. Stilley, III, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 17, 2022. Read the notice at the SEC.

optionsSEC
Jun 2020$5 MPrivate placement after listing$2 to $10 million

Adial Pharmaceuticals, L.L.C.: Private sale, Jun 2020

Investors in this round

6 investors had bought by the notice of Jun 17, 2020: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$365,190
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bankole A. Johnson · Executive Officer
  • Joseph M. Truluck · Executive Officer
  • William B. Stilley, III · Executive Officer, Director
  • Jack W. Reich · Director
  • James K. Anderson · Director
  • James W. Newman, Jr. · Director
  • Kevin W. Schuyler, CFA · Director
  • Robertson H. Gilliland · Director
  • Tony W. Goodman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in CA, IL, NY

Remarks in the notice

  • On the amounts: “Combined purchase price of 2,820,000 shares of common stock (CS) in a registered direct offering & warrants in private placement to purchase 2,115,000 shares of CS with an exercise price of $2.00 per share.”
  • On the use of proceeds: “While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.”

Signed by William B. Stilley, III, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 17, 2020. Read the notice at the SEC.

equity, optionsSEC
Jun 2013$3 MNo. 2$2 to $10 million

Adial Pharmaceuticals, L.L.C.: Raise no. 2, Jun 2013

Investors in this round

35 investors had bought by the notice of Oct 2, 2013: 35 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered; $0 M still to sell
Smallest investment taken
$100,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$395,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Limited Liability Company, incorporated in Virginia

People named in the notice

  • WIlliam Stilley · Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jim Dada, VP Finance. Source: SEC Form D, newest notice filed Oct 2, 2013. Read the notice at the SEC.

equitySEC
Mar 2011$4 MNo. 1$2 to $10 million

Adial Pharmaceuticals, L.L.C.: Raise no. 1, Mar 2011

Investors in this round

0 investors had bought by the notice of Mar 16, 2011: 0 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
$13,755
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Virginia

People named in the notice

  • Bankole A Johnson · Executive Officer, Director · Chairman
  • John F Riccardi · Executive Officer, Director · Chief Financial Officer
  • William B Stilley · Executive Officer, Director · Chief Executive Officer
  • Mike L King · Director
  • Ming D Li · Director
  • Robert S Capon · Director
  • Wendy L Yarno · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John F. Riccardi, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 16, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Adial Pharmaceuticals, L.L.C. chose not to state its revenue in its newest notice of a funding round (Dec 2025).

    SEC Form D · Dec 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Dec 2025

That is all the official record says: Adial Pharmaceuticals, L.L.C. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Adial Pharmaceuticals, L.L.C. are on record.

Investors#

No investor of Adial Pharmaceuticals, L.L.C. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 35 investors.

Largest shareholders today

Institutions holding Adial Pharmaceuticals, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Adial Pharmaceuticals, L.L.C.
NameRoleNamed in
Cary J. ClaiborneChief Executive OfficerDec 2025
Tony W. GoodmanChief Operating OfficerDec 2025
Vinay J. ShahChief Financial OfficerDec 2025
Bankole A. JohnsonExecutive officerOct 2023
Joseph M. TruluckExecutive officerOct 2023
Cary W. ClaiborneExecutive officerFeb 2022
William B. Stilley, IIIExecutive officerFeb 2022
WIlliam StilleyExecutive officerOct 2013
Bankole A JohnsonChairmanMar 2011
John F RiccardiChief Financial OfficerMar 2011
William B StilleyChief Executive OfficerMar 2011
Cary J. ClaiborneChief Executive OfficerDec 2025
James K. AndersonDirectorDec 2025
James W. Newman, Jr.DirectorDec 2025
Kevin W. Schuyler, CFADirectorDec 2025
Robertson H. GillilandDirectorDec 2025
Tony W. GoodmanChief Operating OfficerDec 2025
Cary W. ClaiborneDirectorFeb 2022
William B. Stilley, IIIDirectorFeb 2022
Jack W. ReichDirectorJun 2020
Bankole A JohnsonChairmanMar 2011
John F RiccardiChief Financial OfficerMar 2011
Mike L KingDirectorMar 2011
Ming D LiDirectorMar 2011
Robert S CaponDirectorMar 2011
Wendy L YarnoDirectorMar 2011
William B StilleyChief Executive OfficerMar 2011

Went public since 2018. Its SEC number is that of a company listed on a stock exchange.